Tenax Therapeutics Analyst Price Targets - Benzinga

Tenax Therapeutics Inc

TENXNASDAQ

Trade with Public

Trade with Public

$1.41

-0.10-6.62%

Ult. Agg.: Oct 16, 12:41 PM

$1.51

N/A

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Tenax Therapeutics Analyst Price Targets - Benzinga

Tenax Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tenax Therapeutics (TENX).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

5Buy

4Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$23Upside to Avg. PT+1495.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Aug 11, 2026	Chardan Capital	Gautam Chukka	Downgrade	Buy→Neutral	$27→$5
Aug 11, 2026	Canaccord Genuity	Angela Qian	PT Cut	Buy	$35→$4
Aug 11, 2026	Guggenheim	Seamus Fernandez	PT Cut	Buy	$40→$4
Aug 11, 2026	Evercore ISI Group	Gavin Clark-Gartner	Downgrade	Outperform→In-Line	$39→$5
Aug 10, 2026	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
Jul 31, 2026	Chardan Capital	Gautam Chukka	Maintained	Buy	$27
Jul 29, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Maintained	Overweight	$35
Jul 28, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$35
Jul 22, 2026	Evercore ISI Group	Gavin Clark-Gartner	Initiate	Outperform	$39
Jul 2, 2026	Chardan Capital	Gautam Chukka	Maintained	Buy	$27
Jun 24, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Maintained	Overweight	$35
Jun 22, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$34→$40
Jun 22, 2026	Chardan Capital	Gautam Chukka	Initiate	Buy	$27
Jun 12, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$20→$50
Mar 17, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Initiate	Overweight	$35
Mar 16, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$25→$34
Dec 17, 2025	Guggenheim	Seamus Fernandez	PT Raise	Buy	$14→$25
Sep 8, 2025	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$20
Aug 14, 2025	Guggenheim	Seamus Fernandez	PT Cut	Buy	$15→$14

More with Benzinga EdgeGet Access

Analyst Ratings News

5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Month

U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 350 points during the session. Renewed US-Iran strikes over the weekend sent crude sharply higher Monday, reviving inflation fears and

Avi Kapoor

This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Mizuho analyst

Avi Kapoor

PRO
Guggenheim Downgrades Tenax Therapeutics to Neutral

Guggenheim analyst Seamus Fernandez downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral.

Benzinga Newsdesk

PRO
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5

Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4

Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.

Benzinga Newsdesk

PRO
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5

Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.

Benzinga Newsdesk